Rovafovir etalafenamide

DB14903InvestigationalSmall molecule

Rovafovir etalafenamide is under investigation in clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen).

Mechanism: Pharmacologically active on Reverse transcriptase/RNaseH
Curator reviewed
Formula / weight: C₂₁H₂₄FN₆O₆P · 506.431 g/mol (avg)
Code names: GS-9131

Resolves to

Compound

UNIIU8S0IC8DY7CAS912809-27-9

Structure

InChIKeyOCJRRXHWPBXZSU-BJBBEUPESA-NSMILESCCOC(=O)[C@H](C)N[P@@](=O)(CO[C@H]1O[C@@H](N2C=NC3=C2N=CN=C3N)C(F)=C1)OC1=CC=CC=C1

Targets

Q72547pol

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rovafovir etalafenamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account